View in EDS

Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.

Saved in:
Bibliographic Details
Title: Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.
Authors: Lantermans HC; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Ma F; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Kuil A; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., de Rooij MFM; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Bergkamp ND; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Meer W; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands., van Buul JD; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands., Smit MJ; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Kersten MJ; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands., Spaargaren M; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands., Pals ST; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.
Source: Blood advances [Blood Adv] 2025 May 13; Vol. 9 (9), pp. 2307-2320.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39969206
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lantermans+HC%22">Lantermans HC</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ma+F%22">Ma F</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kuil+A%22">Kuil A</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Rooij+MFM%22">de Rooij MFM</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bergkamp+ND%22">Bergkamp ND</searchLink>; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Meer+W%22">van der Meer W</searchLink>; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Buul+JD%22">van Buul JD</searchLink>; Department of Medical Biochemistry, Vascular Cell Biology Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Section Molecular Cytology at Swammerdam Institute for Life Sciences, Leeuwenhoek Centre for Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Smit+MJ%22">Smit MJ</searchLink>; Amsterdam Institute for Molecular and Life Sciences, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kersten+MJ%22">Kersten MJ</searchLink>; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Spaargaren+M%22">Spaargaren M</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pals+ST%22">Pals ST</searchLink>; Department of Pathology, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.; Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Target & Therapy Discovery, Amsterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 May 13; Vol. 9 (9), pp. 2307-2320.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39969206
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2024014396
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2307
    Titles:
      – TitleFull: Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lantermans HC
      – PersonEntity:
          Name:
            NameFull: Ma F
      – PersonEntity:
          Name:
            NameFull: Kuil A
      – PersonEntity:
          Name:
            NameFull: de Rooij MFM
      – PersonEntity:
          Name:
            NameFull: Bergkamp ND
      – PersonEntity:
          Name:
            NameFull: van der Meer W
      – PersonEntity:
          Name:
            NameFull: van Buul JD
      – PersonEntity:
          Name:
            NameFull: Smit MJ
      – PersonEntity:
          Name:
            NameFull: Kersten MJ
      – PersonEntity:
          Name:
            NameFull: Spaargaren M
      – PersonEntity:
          Name:
            NameFull: Pals ST
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 05
              Text: 2025 May 13
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1